id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-272015-1anph6qi	Dauby, Nicolas	The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment?	2020-10-17		.txt	text/plain	962	19	7	In the same line, ongoing trials are investigating colchicine to prevent hospitalisation in SARS-CoV-2 infected subjects, and the rationale is based on anti-inflammatory properties, that are partly shared Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19 The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients Hydroxychloroquine: from malaria to autoimmunity Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 Hydroxychloroquine Use Is Associated with Lower Odds of Persistently Positive Antiphospholipid Antibodies and/or Lupus Anticoagulant in Systemic Lupus Erythematosus Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study An inflammatory cytokine signature predicts COVID-19 severity and survival Longterm hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study Chloroquine inhibits the release of inflammatory cytokines by human lung explants Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis Chloroquine inhibits production of TNF-α, IL-1β and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes Early Hydroxychloroquine but not Chloroquine use reduces ICU admission in COVID-19 patients High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates Colchicine as a possible therapeutic option in COVID-19 infection Selective regulation of cytokine secretion by hydroxychloroquine: inhibition of interleukin 1 alpha (IL-1-alpha) and IL-6 in human monocytes and T cells Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19 Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study World Health Organization Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19 HCQ inhibits the production of the pro-inflammatory cytokines interleukin (IL)-6, TNF-α and IL-1-β by activated macrophages (Sperber et al. 1993; Jang et al. 2006) , which are notoriously associated with COVID-19 severity (Webb et al.; Del Valle et al. 2020 ) and also the production of chemotactic cytokines involved in the recruitment of pro-inflammatory cells in the lungs(Grassin-Delyle et al. 2020).	cache/cord-272015-1anph6qi.txt	txt/cord-272015-1anph6qi.txt
